postinfectious cough
Conditions
Interventions
Experimental group:15 g of active Zihua Wenfei Zhisou Granule three times daily (15 g/bag)
Control group:15 g of Zihua Wenfei Zhisou Granule-matched placebo three times daily (15 g/bag)
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.When signing the informed consent form, the age is between 18 and 65 years old (including 18 and 65 years old) 2.Diagnosis of postinfectious cough; 3. Wind-cold invading lungs syndrome in TCM Zheng; 4. Baseline cough visual analogue scale of 60 mm or more; 5. Cough duration of 3- 6 weeks; 6.Voluntarily provide written and informed consent.
Exclusion criteria
Exclusion criteria: 1.Cough caused by cough variant asthma, upper airway cough syndrome, eosinophilic bronchitis, gastroesophageal reflux cough or any other concomitant conditions; 2.Patients with severe pulmonary diseases such as lung cancer, lung tuberculosis, or lung fibrosis; 3.After inhaling bronchodilator, patients with FEV1/FVC= 32 ppb or Bronchial provocation test positive (for FeNO and Bronchial provocation test, if the center cannot detect it, it can be detected in other qualified tertiary hospitals); 7.Combined with serious cardio-cerebrovascular diseases, malignant tumors, diseases of blood and hematopoietic system, gastrointestinal diseases or other serious or progressive diseases of the system; Or those who are unable to cooperate or unwilling to cooperate due to severe mental illness, severe cognitive impairment, etc; 8.Liver and kidney dysfunction: ALT or AST >2 times the upper limit of normal reference value; And/or serum creatinine >1.5 times the upper limit of normal reference value, or eGFR 10.0*109/L, and/or neutrophil granulocyte > 80%; 10.Patients with temperature of 37.3 degree or above; 11.Patients taking similar medications in the last one week; 12.Have a long history of alcohol or drug abuse; 13.Pregnancy or potential pregnancy or lactation; 14.Allergic constitution or known to be allergic to any component in tested drug; 15.Patients having participated or participating in another trial in last 3 month; 16.Patients unsuitable for clinical trials judged by researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cough relief rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete remission rate of cough;Time to cough relief;Complete remission time of cough;Change from baseline in Cough Evaluation Test (CET) value;Change from baseline in VAS value;Change from baseline in TCM syndrome score;Leicester Cough Questionnaire (LCQ); | — |
Countries
China
Contacts
Public ContactBing Mao, Hongli Jiang
Outcome results
None listed